Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Adverse events in...

    Adverse events in trial dent hopes for Roche hemophilia drug

    Written by savita thakur thakur Published On 2016-11-05T11:06:16+05:30  |  Updated On 5 Nov 2016 11:06 AM IST
    Adverse events in trial dent hopes for Roche hemophilia drug

    Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, the Swiss group said, clouding prospects for its potential blockbuster product.


    The problems relate to thrombosis, or blood clots, with two thromboembolic events and two cases of thrombotic micro angiopathy in patients who were being treated for breakthrough bleeding in the trial of Roche's ACE910.


    Roche said additional monitoring had now been instigated in the study.


    The drugmaker is hoping to win a slice of the $11 billion-a-year hemophilia drug market with ACE910, which represents a threat to more traditional treatments from Novo Nordisk and Shire.


    Deutsche Bank analyst Richard Parkes said the problems suggested that patients were still experiencing breakthrough bleeds despite getting ACE910, cutting the chance that ACE910 was so effective as to abrogate all bleeding risk.


    "We view the news as the first blemish on ACE910's profile," he said.


    A Roche spokesman said the cases involved patients with breakthrough bleeding who were treated using one of two so-called bypassing agents. He added that both agents Shire's FEIBA and Novo's Novo Seven carried thrombosis warnings.


    Haemophilia patients, whose blood does not clot properly, need life-saving infusions of clotting factors, but development of inhibitors in many of those being treated can interfere with efforts to control their bleeding.


    Roche's ACE910, also known as emicizumab, is being closely watched because it could change the way the disease is treated.

    hemophiliahemophilia drugNovo NordiskRichard ParkesRocheShire
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok